About: Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, op

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, op Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 27 August 2018

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) ശാസ്ത്രപ്രബന്ധം (ml) наукова стаття, опублікована у вересні 2018 (uk) article scientifique publié en 2018 (fr) artículu científicu espublizáu n'agostu de 2018 (ast) im September 2018 veröffentlichter wissenschaftlicher Artikel (de) scientific article published on 27 August 2018 (en)
publication date	wds:Q62590239-3D88984E-6DF3-4039-A2D7-67320955CD20
publication date	2018-08-27 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q62590239-CBF48F60-7B4D-4A88-989C-DFB427B57986
language of work or name	English
cites work	wds:Q62590239-081770BE-3E94-4A9E-812D-431F0801B229 wds:Q62590239-19FEEE23-2DE0-494E-B325-48771F1A2F82 wds:Q62590239-2FEA3D22-9376-4E0B-9841-E9CF99BC86CB wds:Q62590239-30C9EA53-2953-49AD-9642-B03C50DDFDA9 wds:Q62590239-349C6A03-60DF-4F61-95BC-7BC33EE01BE7 wds:Q62590239-3DC72B5E-BF4D-4592-B637-E1D2F8FD07D9 wds:Q62590239-3E6251AC-F51E-4801-BBA4-52357E961148 wds:Q62590239-4A368087-FB62-42AE-9179-FA21E30732EB wds:Q62590239-508EE2A0-E69F-4F2D-84C1-BCD80079CADC wds:Q62590239-544BAEFB-B200-4C5D-A71B-89E38E4A8E34 wds:Q62590239-57739860-C868-423C-8A00-0B7D92FCA676 wds:Q62590239-5D5BC597-234C-4AFE-B651-D6A8CD2FC3DC wds:Q62590239-5FCB6B66-4F4E-4BAD-92F1-3B5D52DE264C wds:Q62590239-6AD59FCE-E9C1-4445-8960-FB0A5F14DB9D wds:Q62590239-7CEB3A44-A9CE-4DCE-9131-D0D4ACD9DE70 wds:Q62590239-95BBBEF4-A0BD-483F-910A-7621ED472E51 wds:Q62590239-992A5580-AAC9-4EDA-A2D5-ADB4D0B14914 wds:Q62590239-BD96FEF3-4F74-484B-8557-F9D338E4D8E2 wds:Q62590239-C2189E4D-74F9-4C66-B901-DAA18DA56919 wds:Q62590239-CAD56BF0-05AA-44C7-88EB-AEEEE4E6436B wds:Q62590239-D80638CA-D486-498A-B7C9-C6F81CF6336E wds:Q62590239-D82CE0EF-145C-4D50-879D-4DD0870154A9 wds:Q62590239-DBE0DB44-9DBF-48BD-BAE1-EA17C970A166 wds:Q62590239-E0E99120-AFA7-4641-944D-2A975E142366 wds:Q62590239-EC4A5E2A-FEDC-452B-952B-02D0EFC85F55 wds:Q62590239-FDA1EEE9-B1FE-4D0B-A445-A4521AA9BBFB
cites work	Assessing kidney function--measured and estimated glomerular filtration rate Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial Differential impact on survival of electrocardiographic Q-wave versus enzymatic myocardial infarction after percutaneous intervention: a device-specific analysis of 7147 patients Ticagrelor versus clopidogrel in patients with acute coronary syndromes Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials Long-term use of ticagrelor in patients with prior myocardial infarction Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease Meta-Analysis of Randomized Clinical Trials Comparing Biodegradable Polymer Drug-Eluting Stent to Second-Generation Durable Polymer Drug-Eluting Stents Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial. 2-Year Clinical Follow-Up From the Randomized Comparison of Biolimus-Eluting Stents With Biodegradable Polymer and Sirolimus-Eluting Stents With Durable Polymer in Routine Clinical Practice 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. Race and Sex Differences in the Incidence and Prognostic Significance of Silent Myocardial Infarction in the Atherosclerosis Risk in Communities (ARIC) Study. Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. A Critical Appraisal of Aspirin in Secondary Prevention: Is Less More? Silent Myocardial Infarction and Long-Term Risk of Heart Failure: The ARIC Study.
author name string	wds:Q62590239-0182CECB-D29C-4461-9DD4-480E29040172 wds:Q62590239-4AE5D738-7D3F-4E56-9F6B-5153CAE84796 wds:Q62590239-F0BBC3A3-B460-49C8-B3C1-42E0FE506BD9
author name string	Luc Janssens Kurt Huber Cokky van Meijeren
rdfs:label	Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, op (en) Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, op (nl)
skos:prefLabel	Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, op (en) Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, op (nl)
name	Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, op (en) Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, op (nl)
author	wds:Q62590239-027F9E99-FFBE-4D97-9ADC-105DCBE1F681 wds:Q62590239-0346B38F-134A-4CBF-A7FA-5BB527D964DD wds:Q62590239-18055027-72B3-40B9-A8C9-520B21A8DD22 wds:Q62590239-39CDE7AA-A401-439A-B5AE-B07C8B1DB0EB wds:Q62590239-3BE0C72A-EE51-44C8-BF28-2CCAB79F7DD9 wds:Q62590239-43976548-3E95-4A3C-9D7B-00942254FF1C wds:Q62590239-4531A62B-E6BD-45AA-BDA4-96A4CF503490 wds:Q62590239-56212574-CEF1-428F-9AD2-8EAB286E112A wds:Q62590239-5A032977-400D-4296-AC56-76B0249DA5C3 wds:Q62590239-600D872C-26AA-4E1C-AD8A-D861058E99D9 wds:Q62590239-7DC00FAC-75A3-43C2-A3C7-4651990BA56B wds:Q62590239-8633BB3C-1C6F-4B85-914C-70183E9012C2 wds:Q62590239-865D3CAF-36F2-41C6-BE34-C9727CF63301 wds:Q62590239-8929F103-6B9D-47C5-A36F-5F72375CCAD8 wds:Q62590239-8B12A953-A94C-45F9-9753-4487AB191871 wds:Q62590239-955A3D33-1CE4-4B72-9DE5-75041C6FC67D wds:Q62590239-9B3AD37E-9453-4E92-A097-26EA97ED7171 wds:Q62590239-A59956AE-D13F-4766-89E2-53DD03CA8978 wds:Q62590239-A62FB154-F729-4B2C-9AF1-F613EDF90DBD wds:Q62590239-C9DFB17B-0E29-40DF-B583-7B441B65833F wds:Q62590239-CE0FBDF6-06FA-494C-AEF0-649E4BDC2962 wds:Q62590239-D4CB0D6C-3C83-4B63-B0FE-74B48671A239 wds:Q62590239-D50A3E79-048E-4FEF-88BE-025C11A5C795 wds:Q62590239-D6422787-211D-4861-A2D6-9600A432282F

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software